הליקסט fs 1000 iu
mediline ltd. - factor viii recombinant 1000 iu/dose - lyophilized powder for injection - coagulation factor viii - for the treatment of classical hemophilia ( hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.
רקומבינאט iu 250
teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
רקומבינאט iu 1000
teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
רקומבינאט iu 500
teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
קוג'נייט fs 250 iu
bayer israel ltd - antihemophilic factor (recombinant) sucrose 250 iu/vial - powder for solution for injection - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.
בקסרו
glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - תרחיף להזרקה - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine
גנוטרופין 5.3 מג
pfizer pharmaceuticals israel ltd - somatropin - אבקה להכנת תמיסה לזריקה - somatropin 5.3 mg - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
גנוטרופין 12 מג
pfizer pharmaceuticals israel ltd - somatropin - אבקה להכנת תמיסה לזריקה - somatropin 12 mg - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth witght and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
גרדסיל 9
merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - תרחיף להזרקה - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
טאלץ 80 מג
eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab